Sang Hoon Kim1, Tae-Jung Kim2, Dongho Shin3, Kyung Jae Hur3, Sung-Hoo Hong3, Ji Youl Lee3, U-Syn Ha3,4. 1. Department of Urology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2. Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 3. Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 4. Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Abstract
BACKGROUND: The purpose of this study is to investigate the correlation between ROBO1 expression and prostate cancer aggressiveness. METHODS: ROBO1 expression was evaluated in normal prostate epithelial cells (PrEC) and different prostate cancer cell lines by Western blot analysis. The migration and invasion of native and ROBO1 knockdown cells were evaluated using migration chambers and a Matrigel-coated membrane, respectively. Samples from 145 patients who underwent radical prostatectomy between June 2000 and June 2008, were retrieved from the paraffin files for tissue microarray (TMA) with immunohistochemical analysis. Biochemical recurrence (BCR)-free survival curves were estimated using the Kaplan-Meier and Cox regression methods in two groups of patients classified according to the degree of ROBO1 expression (low or high expression). RESULTS: ROBO1 is highly expressed in the prostate cancer cell lines. All ROBO1 knockdown cells (PC3, 22Rv1 and DU 145) showed markedly decreased migration and invasiveness compared to native cells. In 145 patients with radical prostatectomy, the Kaplan-Meier curves and log-rank test for BCR-free survival stratified by ROBO1 expression in organ-confined (pT2) or not (pT3), showed significant differences in 10-year survival between the ROBO1 high and low expression groups (87.2% versus 52.6% in pT2; P=0.047, 51.0% versus 36.9% in pT3; P=0.033). The multivariable-adjusted model showed a markedly increased hazard ratio (HR) in patients with high ROBO1 expression compared to the patients with low ROBO1expression in every model. CONCLUSIONS: ROBO1 may play an important role in the migration and invasion of prostate cancer cells, and was independently associated with BCR. 2021 Gland Surgery. All rights reserved.
BACKGROUND: The purpose of this study is to investigate the correlation between ROBO1 expression and prostate cancer aggressiveness. METHODS: ROBO1 expression was evaluated in normal prostate epithelial cells (PrEC) and different prostate cancer cell lines by Western blot analysis. The migration and invasion of native and ROBO1 knockdown cells were evaluated using migration chambers and a Matrigel-coated membrane, respectively. Samples from 145 patients who underwent radical prostatectomy between June 2000 and June 2008, were retrieved from the paraffin files for tissue microarray (TMA) with immunohistochemical analysis. Biochemical recurrence (BCR)-free survival curves were estimated using the Kaplan-Meier and Cox regression methods in two groups of patients classified according to the degree of ROBO1 expression (low or high expression). RESULTS: ROBO1 is highly expressed in the prostate cancer cell lines. All ROBO1 knockdown cells (PC3, 22Rv1 and DU 145) showed markedly decreased migration and invasiveness compared to native cells. In 145 patients with radical prostatectomy, the Kaplan-Meier curves and log-rank test for BCR-free survival stratified by ROBO1 expression in organ-confined (pT2) or not (pT3), showed significant differences in 10-year survival between the ROBO1 high and low expression groups (87.2% versus 52.6% in pT2; P=0.047, 51.0% versus 36.9% in pT3; P=0.033). The multivariable-adjusted model showed a markedly increased hazard ratio (HR) in patients with high ROBO1 expression compared to the patients with low ROBO1expression in every model. CONCLUSIONS: ROBO1 may play an important role in the migration and invasion of prostate cancer cells, and was independently associated with BCR. 2021 Gland Surgery. All rights reserved.
Authors: Bernd C Schmid; Günther A Rezniczek; Gerhild Fabjani; Toshiyuki Yoneda; Sepp Leodolter; Robert Zeillinger Journal: Breast Cancer Res Treat Date: 2007-02-01 Impact factor: 4.872
Authors: Alain Latil; Laurent Chêne; Béatrix Cochant-Priollet; Philippe Mangin; Georges Fournier; Philippe Berthon; Olivier Cussenot Journal: Int J Cancer Date: 2003-01-20 Impact factor: 7.396
Authors: Ashraf Dallol; Nancy Fernandes Da Silva; Paolo Viacava; John D Minna; Ivan Bieche; Eamonn R Maher; Farida Latif Journal: Cancer Res Date: 2002-10-15 Impact factor: 12.701
Authors: Hongwei Tang; Peng Wei; Eric J Duell; Harvey A Risch; Sara H Olson; H Bas Bueno-de-Mesquita; Steven Gallinger; Elizabeth A Holly; Gloria Petersen; Paige M Bracci; Robert R McWilliams; Mazda Jenab; Elio Riboli; Anne Tjønneland; Marie Christine Boutron-Ruault; Rudolph Kaaks; Dimitrios Trichopoulos; Salvatore Panico; Malin Sund; Petra H M Peeters; Kay-Tee Khaw; Christopher I Amos; Donghui Li Journal: Carcinogenesis Date: 2014-01-13 Impact factor: 4.741